文献速递浆细胞疾病淋巴瘤

地塞米松在多发性骨髓瘤和AL淀粉样变性中的过去、现在与未来

Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis.
PubMed 文献 · J Clin Oncol · 2026-01-27

地塞米松半个多世纪以来是浆细胞疾病治疗骨干,但约40mg每周一次长期使用可致剂量依赖性毒性如白内障和感染。近5年试验显示减激素方案在多发性骨髓瘤中有效且耐受性更好。综述评估地塞米松在现代治疗中的地位,建议新诊断老年/虚弱患者1-2周期后计划停用,维持期风险获益比不利,AL淀粉样变性40mg每周一次6个月过度。

要点

  • 新诊断MM老年/虚弱患者支持1-2周期后计划停用地塞米松。
  • 维持治疗中延长地塞米松风险获益比不利。
  • AL淀粉样变性40mg每周一次6个月过度,可能致容量负荷过重。

核心结论

  • 地塞米松在浆细胞疾病中历史地位重要,但减激素方案值得前瞻性研究。

研究设计与样本

  • 综述,讨论近5年试验及研究,全面评估地塞米松在现代治疗中的作用。

主要发现

  • 约40mg每周一次地塞米松常持续数月或数年,可致剂量依赖性毒性如白内障和感染。
  • 急性毒性如失眠或足部水肿即使低级别也可显著干扰生活质量。
  • 新诊断MM中稳健数据支持老年和虚弱患者1-2周期后计划停用地塞米松。
  • 复发/难治MM中随机试验显示每周一次地塞米松在双药方案中有价值,但在三药和四药方案中贡献不确定。
  • AL淀粉样变性中地塞米松40mg每周一次6个月过度,可能致容量负荷过重。

关键数值与推荐

  • 地塞米松剂量约40mg每周一次常持续数月或数年。
  • 新诊断MM老年和虚弱患者1-2周期后计划停用地塞米松。
  • AL淀粉样变性地塞米松40mg每周一次6个月被视为过度。
  • CD38靶向单抗预给药地塞米松1-2周期后不再需要。
  • 支持治疗地塞米松4-8mg按需常足够。

临床怎么用

  • 新诊断MM老年/虚弱患者1-2周期后计划停用地塞米松。
  • 维持治疗避免延长地塞米松。
  • AL淀粉样变性避免40mg每周一次6个月,警惕容量负荷过重。
  • CD38单抗预给药1-2周期后停用地塞米松。
  • 支持治疗按需使用4-8mg地塞米松。

局限性

  • 缺乏减激素方案在浆细胞疾病全谱的前瞻性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For over half a century, dexamethasone has been a backbone of treatment regimens for plasma cell disorders such as multiple myeloma (MM) and light-chain (AL) amyloidosis. Dexamethasone doses of approximately 40 milligrams (mg) once weekly are often continued for months or years despite accumulating evidence that they can cause dose-dependent toxicities such as cataracts and infections. Acute dexamethasone-related toxicities such as insomnia or pedal edema, even if low-grade by clinical criteria, can significantly interfere with patient quality of life. In the past 5 years, several trials have demonstrated the efficacy and improved tolerability of corticosteroid-sparing regimens in MM. In this review, we discuss these and other studies to comprehensively assess the role of dexamethasone in the modern era. In newly diagnosed MM, robust data support planned dexamethasone discontinuation after one to two cycles in older and frailer patients. In the maintenance setting, the risk-benefit ratio of prolonged dexamethasone is unfavorable. While randomized trials have shown that once-weekly dexamethasone adds value within doublet regimens in relapsed/refractory MM, its contribution to triplet and quadruplet regimens is uncertain. Furthermore, data suggest that indefinite dexamethasone may actually limit the feasibility and efficacy of subsequent postprogression therapies. In AL amyloidosis, dexamethasone 40 mg once weekly for 6 months is excessive and may predispose patients to volume overload. In our review, we also discuss dexamethasone as a premedication for CD38-targeted monoclonal antibodies (where it is no longer required after one to two cycles) and for supportive care (where lower doses of 4-8 mg as needed can often suffice). Despite the historical inertia of corticosteroid-containing regimens in clinical trials and practice guidelines, corticosteroid-sparing regimens warrant prospective investigation across the gamut of plasma cell disorders.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Banerjee R, King T, Faiman B, et al. Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis. J Clin Oncol. 2026. PMID: 41592262. doi:10.1200/JCO-25-01713

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。